Home > Insider Trading > Filing (0001127602-15-025709)

Filing Details

Accession Number:: 0001127602-15-025709
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2015-08-24 18:22:28
Reporting Period:: 2015-08-24

Filing Date:: 2015-08-24
Accepted Time:: 2015-08-24 18:22:28
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1520262	Alkermes Plc.	ALKS	Pharmaceutical Preparations (2834)	981007018

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1524823	Shane Cooke	Connaught House 1 Burlington Road Dublin 4 Ireland	President, Alkermes Plc	No	Yes	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Ordinary Shares	Acquisiton	2015-08-24	18,000	$14.60	58,640	No	4	M	Direct
Ordinary Shares	Disposition	2015-08-24	1,000	$53.40	57,640	No	4	S	Direct
Ordinary Shares	Disposition	2015-08-24	1,200	$54.65	56,440	No	4	S	Direct
Ordinary Shares	Disposition	2015-08-24	2,500	$56.67	53,940	No	4	S	Direct
Ordinary Shares	Disposition	2015-08-24	5,661	$57.78	48,279	No	4	S	Direct
Ordinary Shares	Disposition	2015-08-24	5,107	$58.64	43,172	No	4	S	Direct
Ordinary Shares	Disposition	2015-08-24	2,532	$59.41	40,640	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	M	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct

Reported Derivative Transactions

Show Other Fields >>

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Ordinary Shares	Employee Stock Option (Right to Buy)	Disposition	2015-08-24	18,000	$0.00	18,000	$14.60

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
106,000		2021-10-05	No	4	M	Direct

Footnotes

This option exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $53.05 to $53.91. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $54.28 to $55.16. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $56.01 to $57.00. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $57.04 to $58.03. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $58.05 to $59.02. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $59.0675 to $59.77. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
The option becomes exercisable in equal annual installments over a four year period, at the rate of 25% per year commencing on 10/5/12.